SCHEMBL5161664

SCHEMBL5161664

CC(C)OC(=O)CC(=O)c1ccco1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERCC5 P28715 1/20 0.54
FEN1 P39748 1/20 0.54
RAB9A P51151 5/20 0.52
NPC1 O15118 4/20 0.52
TSHR P16473 2/20 0.51
SMN1; SMN2 Q16637 3/20 0.47
TP53 P04637 3/20 0.47
HPGD P15428 4/20 0.46
HSD17B10 Q99714 3/20 0.46
POLB P06746 3/20 0.46
ALOX15 P16050 2/20 0.46
MAPT P10636 2/20 0.46
ALDH1A1 P00352 1/20 0.46
RECQL P46063 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
USP2 O75604 1/20 0.46
EIF4H Q15056 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3836770 0.84 ERCC5 (0.51) ERCC5FEN1RAB9ANPC1TSHR
SCHEMBL4459612 0.83 ERCC5 (0.61) ERCC5FEN1RAB9ANPC1SMN1; SMN2
SCHEMBL1126497 0.79 ERCC5 (0.56) ERCC5FEN1RAB9ANPC1TSHR
SCHEMBL6320074 0.78 ERCC5 (0.74) ERCC5FEN1RAB9ANPC1TSHR
SCHEMBL5036990 0.78 NPC1 (0.63) RAB9ANPC1TSHRSMN1; SMN2HPGD
SCHEMBL5160673 0.77 NPC1 (0.57) ERCC5FEN1RAB9ANPC1SMN1; SMN2
SCHEMBL29054123 0.77 ERCC5 (0.54) ERCC5FEN1RAB9ANPC1TSHR
SCHEMBL28020549 0.77 ERCC5 (0.57) ERCC5FEN1SMN1; SMN2HPGDHSD17B10
SCHEMBL27986049 0.77 ALDH1A1 (0.49) ERCC5FEN1RAB9ANPC1HPGD
SCHEMBL7070914 0.77 ERCC5 (0.71) ERCC5FEN1RAB9ANPC1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO ERCC5 1067/4885FEN1 1305/4885RAB9A 3428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.